他汀类药物不良反应及相关因素的研究进展

被引：16

作者：

杜贺

陈少萍

机构：

[1] 第二军医大学长海医院心血管内科

来源：

中国心血管杂志 | 2014年 / 19卷 / 06期

关键词：

他汀类药物; 不良反应; 相关因素; 进展;

D O I：

暂无

中图分类号：

R95 [药事组织];

学科分类号：

100406 [军事预防医学];

摘要：

<正>大量研究奠定了他汀类药物在心血管疾病一级和二级预防中不可动摇的地位,强化调脂的理念已经深入临床。他汀类药物具有良好的耐受性,不良反应少,对肝脏和肌肉潜在的不良反应已得到医患重视。但是目前他汀还存在临床应用、临床安全性等众多问题,2012年2月29日,美国食品药物管理局(FDA)的官方网站上又发布了有关他汀类药物说明书需修改的告示,因此重新认识他汀的安全性对于贯彻指南、推动临床降脂实践非常必要。本文重点围绕他汀类药

引用

页码：463 / 466

页数：4

共 19 条

[1]

Simvastatin impairs exercise training adaptations.[J].Catherine R. Mikus;Leryn J. Boyle;Sarah J. Borengasser;Douglas J. Oberlin;Scott P. Naples;Justin Fletcher;Grace M. Meers;Meghan Ruebel;M. Harold Laughlin;Kevin C. Dellsperger;Paul J. Fadel;John P. Thyfault.Journal of the American College of Cardiology.2013,

[2]

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis [J].

Yates, Thomas ;

Ner, Steven M. Haff ;

Schulte, Phillip J. ;

Thomas, Laine ;

Huffman, Kim M. ;

Bales, Connie W. ;

Califf, Robert M. ;

Holman, Rury R. ;

McMurray, John J. V. ;

Bethel, M. Angelyn ;

Tuomilehto, Jaakko ;

Davies, Melanie J. ;

Kraus, William E. .

LANCET, 2014, 383 (9922) :1059-1066

[3]

Apolipoprotein E, Statins, and Risk of Intracerebral Hemorrhage [J].

Woo, Daniel ;

Deka, Ranjan ;

Falcone, Guido J. ;

Flaherty, Matthew L. ;

Haverbusch, Mary ;

Martini, Sharyl R. ;

Greenberg, Steven M. ;

Ayres, Alison M. ;

Sauerbeck, Laura ;

Kissela, Brett M. ;

Kleindorfer, Dawn O. ;

Moomaw, Charles J. ;

Anderson, Christopher D. ;

Broderick, Joseph P. ;

Rosand, Jonathan ;

Langefeld, Carl D. ;

Woo, Jessica G. .

STROKE, 2013, 44 (11) :3013-3017

[4]

Outcomes of Statin Myopathy After Statin Withdrawal.[J].Ryan Armour;Lan Zhou.Journal of Clinical Neuromuscular Disease.2013, 3

[5]

Effect of Statins on Skeletal Muscle Function [J].

Parker, Beth A. ;

Capizzi, Jeffrey A. ;

Grimaldi, Adam S. ;

Clarkson, Priscilla M. ;

Cole, Stephanie M. ;

Keadle, Justin ;

Chipkin, Stuart ;

Pescatello, Linda S. ;

Simpson, Kathleen ;

White, C. Michael ;

Thompson, Paul D. .

CIRCULATION, 2013, 127 (01) :96-103

[6]

Antibody levels correlate with creatine kinase levels and strength in anti–3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase–associated autoimmune myopathy.[J].Jessie L. Werner;Lisa Christopher‐Stine;Sharon R. Ghazarian;Katherine S. Pak;Jordan E. Kus;Natalie R. Daya;Thomas E. Lloyd;Andrew L. Mammen.Arthritis & Rheumatism.2012, 12

[7]

Statin use and the risk of bladder cancer: a population-based case–control study.[J].Chien-Chun Kuo;Hui-Fen Chiu;I-Ming Lee;Hsin-Wei Kuo;Chien-Te Lee;Chun-Yuh Yang.Expert Opinion on Drug Safety.2012, 5

[8]

Increased frequency of DRB1*11:01 in anti–hydroxymethylglutaryl‐coenzyme a reductase–associated autoimmune myopathy.[J].Andrew L. Mammen;Daniel Gaudet;Diane Brisson;Lisa Christopher‐Stine;Thomas E. Lloyd;Mary S. Leffell;Andrea A. Zachary.Arthritis Care Res.2012, 8

[9]

Statins and the Risk of Cancer After Heart Transplantation [J].

Froehlich, Georg Marcus ;

Rufibach, Kaspar ;

Enseleit, Frank ;

Wolfrum, Mathias ;

von Babo, Michelle ;

Frank, Michelle ;

Berli, Reto ;

Hermann, Mathias ;

Holzmeister, Johannes ;

Wilhelm, Markus ;

Falk, Volkmar ;

Noll, Georg ;

Luescher, Thomas F. ;

Ruschitzka, Frank .

CIRCULATION, 2012, 126 (04) :440-447

[10]

Safety of statin therapy in patients with mitochondrial diseases.[J].Fady Hannah-Shmouni;Ahmad Al-Sarraf;Jiri Frohlich;Michelle M. Mezei;Sandra Sirrs;Andre Mattman.Journal of Clinical Lipidology.2012,

← 1 2 →